P21 (P021)

No, though they are related. P21 was derived from CNTF (ciliary neurotrophic factor), which happens to be one of many active components found in Cerebrolysin. While P21 specifically mimics CNTF's neurotrophic actions via its DGGL active sequence with an adamantane modification, Cerebrolysin is a complex mixture of many different neurotrophic peptides and amino acids derived from pig brain tissue. P21 is a single, well-defined synthetic compound with a specific mechanism of action, while Cerebrolysin contains hundreds of different bioactive molecules.

No, P21 has not completed formal human clinical trials as of 2025. All published efficacy and safety data comes from extensive preclinical studies in mice, including normal mice and multiple Alzheimer's disease transgenic models. Studies have demonstrated safety in continuous treatment periods of up to 12 months in mice without the adverse effects (anorexia, weight loss, hyperalgesia) associated with parent molecule CNTF. The compound is used in the nootropics research community, but no controlled human data has been published.

P21 promotes neurogenesis through a specific signaling cascade. It interacts with the CNTF signaling system to inhibit leukemia inhibitory factor (LIF) signaling, which leads to increased expression of brain-derived neurotrophic factor (BDNF) in the hippocampus. The elevated BDNF then stimulates neural progenitor cells in the subgranular zone of the dentate gyrus to proliferate, differentiate into neurons, and mature into fully functional cells that integrate into existing hippocampal circuits. BDNF also supports the dendritic growth and synapse formation of these new neurons.

The adamantane modification is the addition of an adamantylated glycine residue at the C-terminal of the CNTF tetrapeptide (DGGL). Adamantane is a rigid, lipophilic cage molecule (like a carbon diamond cage) that dramatically increases the compound's ability to cross the blood-brain barrier by enhancing lipophilicity. It also protects the peptide from degradation by exopeptidases, significantly increasing its metabolic stability and half-life. Without this modification, the DGGL peptide would be rapidly degraded in the bloodstream and unable to reach the brain.

In preclinical Alzheimer's mouse models, P21 demonstrated remarkable disease-modifying effects: reducing tau hyperphosphorylation, lowering soluble amyloid-beta levels, rescuing synaptic deficits, and restoring cognitive function. The 12-month treatment study in 3xTg-AD mice is particularly compelling. However, mouse models of Alzheimer's disease do not perfectly replicate the human condition. Whether P21 would produce similar benefits in human Alzheimer's patients remains unknown and would require rigorous clinical testing.

Intranasal spray is the most commonly used route in the nootropics research community, as it delivers the peptide efficiently to the brain via the olfactory pathway while bypassing first-pass liver metabolism. In the original preclinical studies, P21 was administered orally in the diet and demonstrated BBB permeability and efficacy via this route, confirming oral bioavailability. Subcutaneous injection is an alternative for precise dosing. All three routes have been shown to deliver the compound to the brain effectively.

Preclinical studies used treatment periods ranging from weeks to 12 months, with cognitive benefits appearing within weeks and disease-modifying effects demonstrated over long-term treatment. For nootropic use, cycles of 8-12 weeks are commonly referenced in the research community. The compound showed excellent safety in the longest study (12 months continuous treatment in mice). Some benefits from neurogenesis may persist after discontinuation, as newly formed neurons and synaptic connections remain. The optimal duration for human use has not been formally established.